Potential Breakthrough in Dual Cellular Therapy for Advanced and Metastatic Solid Tumors
Roswell Park Comprehensive Cancer Center is conducting a phase 1 clinical trial, OASIS, to evaluate the effectiveness of a genetically modified oncolytic virus, CF33-CD19, combined with blinatumomab, in treating advanced or metastatic solid tumors. This innovative approach aims to extend the benefits of cellular immunotherapies to patients with cancers resistant to traditional therapies.
Imugene Doses First Australian Patient in Phase 1b Trial of Azer-Cel for B-Cell Lymphoma
• Imugene has dosed the first Australian patient in a Phase 1b trial of azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
• The trial aims to evaluate azer-cel's tolerability, safety, and clinical activity in DLBCL patients who have failed previous autologous CAR T-cell treatments.
• Azer-cel offers an off-the-shelf solution, potentially reducing treatment times and increasing patient access compared to traditional autologous CAR T-cell therapies.
• Promising outcomes from US trial sites showed complete responses in subjects who received lymphodepletion chemotherapy and interleukin-2 (IL-2) after failing prior treatments.
© Copyright 2025. All Rights Reserved by MedPath